Pulmonary embolism (PE) risk stratification is a foundational step in guiding acute management decisions, since treatment intensity ranges from anticoagulation alone to advanced catheter-based or systemic reperfusion therapy. This overview summarizes the general concepts clinicians use to categorize PE severity, intended as an educational review rather than a clinical protocol.
Why Risk Stratification Matters
Not all pulmonary emboli carry the same immediate risk. A small, peripheral PE in a hemodynamically stable patient calls for a different management intensity than a large central PE causing right ventricular strain or hemodynamic compromise. Risk stratification frameworks help clinicians categorize patients to guide decisions around monitoring level, anticoagulation alone versus advanced therapy, and escalation pathways.
What Are the General PE Severity Categories?
Clinical frameworks commonly describe PE severity along a spectrum, generally organized around hemodynamic status and evidence of right ventricular (RV) strain:
- Low-risk (non-massive) PE — hemodynamically stable, without evidence of RV dysfunction or myocardial injury on biomarkers or imaging
- Submassive (intermediate-risk) PE — hemodynamically stable but with evidence of RV strain on echocardiography or CT, elevated cardiac biomarkers (such as troponin or BNP), or both
- Massive (high-risk) PE — associated with sustained hypotension, cardiogenic shock, or cardiac arrest attributable to the PE
This categorization is a widely referenced conceptual framework in PE literature and clinical guidelines; exact criteria and terminology can vary between specific guideline bodies and institutions.
What Factors Typically Inform Risk Assessment?
Clinicians typically draw on a combination of the following when assessing PE severity:
- Hemodynamic parameters — blood pressure, heart rate, and evidence of shock
- Right ventricular function — assessed via echocardiography or CT signs such as RV-to-LV ratio
- Cardiac biomarkers — troponin and natriuretic peptides (e.g., BNP/NT-proBNP) as indicators of cardiac strain
- Clinical prediction scores — validated tools such as the Pulmonary Embolism Severity Index (PESI) or simplified PESI, which incorporate factors like age, comorbidities, and vital signs to estimate short-term mortality risk
- Clot burden and location on imaging, particularly central versus peripheral involvement
How Does Risk Category Generally Inform Management Pathways?
Risk stratification broadly informs, but does not by itself dictate, the intensity of intervention considered by the treating team:
- Low-risk PE is often managed with anticoagulation alone, and select patients may be appropriate for outpatient management per institutional protocols
- Submassive PE management is more variable and often involves closer monitoring, with some patients considered for advanced therapies such as catheter-directed approaches based on individualized risk-benefit assessment
- Massive PE typically triggers escalation to advanced reperfusion strategies, including systemic thrombolysis, catheter-based thrombectomy or thrombolysis, or mechanical circulatory support, depending on the clinical scenario and institutional capability
Some institutions use a multidisciplinary Pulmonary Embolism Response Team (PERT) model to rapidly evaluate intermediate- and high-risk PE cases and coordinate the appropriate management pathway.
A Note on Scope
This article summarizes general risk stratification concepts for educational purposes and does not constitute clinical guidance or a treatment protocol. Specific management decisions should follow current institutional protocols and published clinical practice guidelines, and should be individualized to the patient by the treating clinical team.
Frequently Asked Questions
What is the PESI score used for?
The Pulmonary Embolism Severity Index (PESI) and its simplified version are validated clinical prediction tools that estimate short-term mortality risk in PE patients, incorporating factors such as age, comorbid conditions, and vital signs, to help inform triage and management-intensity decisions.
Is submassive PE the same as intermediate-risk PE?
These terms are generally used interchangeably in much of the PE literature to describe hemodynamically stable patients with evidence of RV strain or biomarker elevation, though exact terminology can vary by guideline source.
Why do some intermediate-risk PE patients receive advanced therapy while others do not?
Management within the submassive/intermediate-risk category is individualized, weighing factors such as the degree of RV strain, bleeding risk, clinical trajectory, and institutional resources. This is an area of ongoing clinical judgment rather than a uniform protocol.
Related INVAMED Resources
- Pulmonary Embolism Management — INVAMED's PE-related device portfolio
- Deep Vein Thrombosis (DVT) — related venous thromboembolism devices
- Contact INVAMED — request more information
Medical Disclaimer: This article is provided for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for consultation with a qualified healthcare professional. Product indications, availability, and regulatory status vary by country. Always refer to the official Instructions for Use (IFU) and consult a licensed physician for guidance specific to your situation. INVAMED devices are intended for use by trained healthcare professionals.